Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M105,308Revenue $M19,960Net Margin (%)8.9Z-Score3.7
Enterprise Value $M107,924EPS $1.1Operating Margin %17.1F-Score0
P/E(ttm))60.5Cash Flow Per Share $0Pre-tax Margin (%)11.9Higher ROA y-yN
Price/Book60.610-y EBITDA Growth Rate %0Quick Ratio1.3Cash flow > EarningsN
Price/Sales5.35-y EBITDA Growth Rate %0Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-45.1ROA % (ttm)6.2Higher Current Ratio y-yN
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)42.7Less Shares Outstanding y-yN
Payout Ratio %151Shares Outstanding M1,594ROI % (ttm)22.2Gross Margin Increase y-yN

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVJohn Paulson 2014-12-31 Sold Out -3.1%$52.9 - $69.71
($63.24)
$ 66.074%Sold Out0
ABBVSteve Mandel 2014-12-31 Sold Out -1.2%$52.9 - $69.71
($63.24)
$ 66.074%Sold Out0
ABBVGeorge Soros 2014-12-31 Sold Out -0.66%$52.9 - $69.71
($63.24)
$ 66.074%Sold Out0
ABBVJean-Marie Eveillard 2014-12-31 Buy 0.16%$52.9 - $69.71
($63.09)
$ 66.075%New holding1,016,097
ABBVMario Gabelli 2014-12-31 Add0.01%$52.9 - $69.71
($63.09)
$ 66.075%Add 232.85%34,557
ABBVJohn Paulson 2014-09-30 Buy 3.1%$52.05 - $59.62
($55.51)
$ 66.0716%New holding13,000,000
ABBVSteve Mandel 2014-09-30 Buy 1.2%$52.05 - $59.62
($55.51)
$ 66.0716%New holding5,247,201
ABBVGeorge Soros 2014-09-30 Add0.6%$52.05 - $59.62
($55.51)
$ 66.0716%Add 924.76%1,537,146
ABBVJoel Greenblatt 2014-09-30 Reduce-0.06%$52.05 - $59.62
($55.51)
$ 66.0716%Reduce -89.36%9,460
ABBVJoel Greenblatt 2014-06-30 Reduce-0.11%$46.46 - $56.79
($52.4)
$ 66.0721%Reduce -61.19%88,923
ABBVGeorge Soros 2014-06-30 Reduce-0.1%$46.46 - $56.79
($52.4)
$ 66.0721%Reduce -57.14%150,000
ABBVKen Fisher 2014-06-30 Add0.06%$46.46 - $56.79
($52.4)
$ 66.0721%Add 76.13%1,104,609
ABBVNWQ Managers 2014-06-30 Buy 0.05%$46.46 - $56.79
($52.4)
$ 66.0721%New holding83,878
ABBVGeorge Soros 2014-03-31 Reduce-0.35%$46.83 - $53.68
($50.6)
$ 66.0723%Reduce -69.50%350,000
ABBVVanguard Health Care Fund 2014-03-31 Sold Out -0.28%$46.83 - $53.68
($50.59)
$ 66.0723%Sold Out0
ABBVJoel Greenblatt 2014-03-31 Add0.1%$46.83 - $53.68
($50.6)
$ 66.0723%Add 120.38%229,149
ABBVKen Fisher 2014-03-31 Reduce-0.06%$46.83 - $53.68
($50.59)
$ 66.0723%Reduce -45.03%627,139
ABBVDavid Dreman 2014-03-31 Sold Out -0.02%$46.83 - $53.68
($50.6)
$ 66.0723%Sold Out0
ABBVVanguard Health Care Fund 2013-12-31 Reduce-1.03%$44.52 - $54.32
($49.14)
$ 66.0726%Reduce -79.44%1,739,600
ABBVJoel Greenblatt 2013-12-31 Reduce-0.06%$44.52 - $54.32
($49.14)
$ 66.0726%Reduce -26.75%103,981
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC 2015-03-02Sell25,000$60.36.55view
RICHMOND TIMOTHY J.SVP, Human Resources 2015-03-02Sell14,388$60.336.5view
SALEKI-GERHARDT AZITASVP, Operations 2015-02-27Sell2,112$60.476.25view
HURWICH THOMAS A.VP, Controller 2015-02-27Sell1,185$60.576.08view
RICHMOND TIMOTHY J.SVP, Human Resources 2015-02-17Sell241$58.79.45view
CHASE WILLIAM JEVP, CFO 2014-12-22Sell8,495$68-5.51view
HURWICH THOMAS A.VP, Controller 2014-11-24Sell1,500$67.81-5.25view
GONZALEZ RICHARD AChairman of the Board and CEO 2014-03-04Sell4,799$51.225.49view
ALBAN CARLOSEVP, Commercial Operations 2014-03-03Sell2,882$50.0928.27view
CHASE WILLIAM JEVP, CFO 2014-03-03Sell3,948$50.2227.94view

Press Releases about ABBV :

    Quarterly/Annual Reports about ABBV:

    News about ABBV:

    Articles On GuruFocus.com
    Analyzing Chris Davis' Top Holdings Apr 14 2015 
    Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
    AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
    Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
    AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
    Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
    Dogs Of The S&P 500 - No Dividend Alternatives Are Cheaper! Feb 21 2015 
    Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
    Gilead Sciences Offering Fresh Wave Of Competition To AbbVie’s Viekira Pak Feb 06 2015 
    Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 Feb 05 2015 


    More From Other Websites
    Biogen Earnings Preview: What To Look For Apr 23 2015
    AbbVie Profit Rises on Broad Sales Growth Apr 23 2015
    The overseas tax tactic is back Apr 23 2015
    Doomsday Plan for AbbVie Means Preserving Profits at All Costs Apr 23 2015
    AbbVie Beats Q1 Estimates; Novartis, Alexion Mixed Apr 23 2015
    AbbVie Beats Earnings on Humira and HCV Sales, Ups View - Analyst Blog Apr 23 2015
    Shire Gets Dropped from AQR Capital’s Portfolio Apr 23 2015
    AbbVie: Wait, I Thought It Was Good News? Apr 23 2015
    AbbVie raises outlook as Humira again delivers earnings beat Apr 23 2015
    AbbVie raises outlook as Humira again delivers earnings beat Apr 23 2015
    Abbvie's CEO Gonzalez: We're Now In Pharma's 'Top Tier' Apr 23 2015
    AbbVie (ABBV) Tops 1Q Earnings and Revenue Estimates - Tale of the Tape Apr 23 2015
    Morning Movers: AbbVie Gains on Earnings, Hepatitis-C Sales; General Motors Drops Apr 23 2015
    AbbVie Inc Earnings Call scheduled for 9:00 am ET today Apr 23 2015
    Enanta Announces U.S. FDA Grants Priority Review for AbbVie’s Investigational, All-Oral,... Apr 23 2015
    AbbVie tops Street 1Q forecasts Apr 23 2015
    AbbVie tops Street 1Q forecasts Apr 23 2015
    AbbVie Reports First-Quarter 2015 Financial Results Apr 23 2015
    ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 23 2015
    AbbVie Profit Tops Estimates as Hepatitis C Drug Sales Increase Apr 23 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK